Table 1. Patient, disease, and treatment baseline characteristics.

Characteristics	N (%) or median (range)
No. of patients	19
Age (years)	67.2 (40.9–89.6)
Sex
Male	11 (57.9)
Female	8 (42.1)
ECOG
0	8 (42.1)
1	8 (42.1)
2	3 (15.8)
Disease extent
Resectable	16 (84.2)
Borderline resectable	3 (15.8)
Baseline CA 19-9 (U/mL)	49.9 (1.0–10,000)
Neoadjuvant chemotherapy	5 (26.3)
Duration (months)	4 (1.5–5.0)
Regimen
FFX	2
GnP	2
FOLFOX plus bevacizumab	1
Adjuvant chemotherapy	15 (78.9)
Duration (months)	3.0 (2.0–6.0)
Regimen
FFX	2
GnP	2
FFX and GnP	1
Gemcitabine	6
Gemcitabine plus capecitabine	4
Surgery type
Whipple procedure	14 (73.7)
Distal pancreatectomy	3 (15.8)
Total pancreatectomy	2 (10.5)
Primary tumor size (cm)	2.9 (1.0–5.8)
Positive margins	4 (21.1)
Node positive	8 (42.1)
Disease grade
II	13 (68.4)
III	6 (31.6)

ECOG, Eastern Cooperative Oncology Group; CA 19-9, cancer antigen 19-9; FFX, FOLFIRINOX; GnP, gemcitabine plus nab-paclitaxel.